Suppressing c-Abl in Parkinson disease

被引：1
|
作者：
Crunkhorn, Sarah
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2023年 / 22卷 / 03期
关键词：
D O I：
10.1038/d41573-023-00024-w
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：183 / 183
页数：1
相关论文
共 50 条
  • [31] c-abl研究进展
    李伟
    国外医学(分子生物学分册), 2002, (01) : 50 - 52
  • [32] c-ABL AND INSULIN RECEPTOR SIGNALLING
    Genua, Marco
    Pandini, Giuseppe
    Cassarino, Maria Francesca
    Messina, Rosa Linda
    Frasca, Francesco
    VITAMINS AND HORMONES INSULIN AND IGFS, 2009, 80 : 77 - 105
  • [33] The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease
    Karuppagounder, Senthilkumar S.
    Wang, Hu
    Kelly, Terence
    Rush, Roger
    Nguyen, Richard
    Bisen, Shivani
    Yamashita, Yoko
    Sloan, Nicholas
    Dang, Brianna
    Sigmon, Alexander
    Lee, Hyeun Woo
    Lee, Shirley Marino
    Watkins, Leslie
    Kim, Erica
    Brahmachari, Saurav
    Kumar, Manoj
    Werner, Milton H.
    Dawson, Ted M.
    Dawson, Valina L.
    SCIENCE TRANSLATIONAL MEDICINE, 2023, 15 (679)
  • [34] c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease
    Mahul-Mellier, Anne-Laure
    Fauvet, Bruno
    Gysbers, Amanda
    Dikiy, Igor
    Oueslati, Abid
    Georgeon, Sandrine
    Lamontanara, Allan J.
    Bisquertt, Alejandro
    Eliezer, David
    Masliah, Eliezer
    Halliday, Glenda
    Hantschel, Oliver
    Lashuel, Hilal A.
    HUMAN MOLECULAR GENETICS, 2014, 23 (11) : 2858 - 2879
  • [35] Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson?s disease
    Walsh, Ryan R.
    Damle, Nitin K.
    Mandhane, Sanjay
    Piccoli, Steven P.
    Talluri, Ravi S.
    Love, Damon
    Yao, Siu-Long
    Ramanathan, Vikram
    Hurko, Orest
    PARKINSONISM & RELATED DISORDERS, 2023, 108
  • [36] c-Abl activates RIPK3 signaling in Gaucher disease
    Yanez, M. J.
    Campos, F.
    Marin, T.
    Klein, A. D.
    Futerman, A. H.
    Alvarez, A. R.
    Zanlungo, S.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2021, 1867 (05):
  • [37] A novel brain penetrant c-Abl tyrosine kinase inhibitor: Paving a path forward to success in disease modification in Parkinson's disease
    Simuni, Tanya
    Merchant, Kalpana
    PARKINSONISM & RELATED DISORDERS, 2023, 108
  • [38] Regulation of the C-Abl and Bcr-Abl tyrosine kinases
    Hantschel, O
    Superti-Furga, G
    NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2004, 5 (01) : 33 - 44
  • [39] EVOLUTION OF ONCOGENES - FROM C-ABL TO V-ABL
    WANG, JYJ
    NATURE, 1983, 304 (5925) : 400 - 400
  • [40] The C-terminus of C-ABL is required for proliferation and viability signalling in a C-ABL/EPO receptor fusion protein.
    Okuda, K
    VanEtten, R
    DAndrea, A
    Griffin, JD
    BLOOD, 1997, 90 (10) : 1100 - 1100
12345